FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma (05-7-2018)

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected... Continue Reading

Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma (04-5-2018)

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual... Continue Reading

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma (01-15-2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected... Continue Reading

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma (01-12-2018)

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment... Continue Reading

FDA Approves Opdivo for Adjuvant Treatment of Melanoma (01-9-2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (01-8-2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma (09-28-2017)

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European... Continue Reading

Investigational Melanoma Drug Shrinks Tumors in Phase III Trial (07-2-2013)

In a Phase III clinical trial, the investigational drug T-VEC (talimogene laherparepvec) produced durable responses in people with advanced melanoma.  These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

Anti-PD-1 Drugs Promising for Advanced Melanoma (07-1-2013)

In Phase I clinical trials, investigational drugs that target a protein known as PD-1 are showing promise for the treatment of advanced melanoma. Results from two of the trials were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading

Selumetinib Active Against Melanoma of the Eye (06-26-2013)

In a Phase II clinical trial, the investigational targeted drug selumetinib resulted in tumor shrinkage in half of patients with advanced melanoma of the eye. These results were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading

Next Page »